Cargando…
Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo
PURPOSE: Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we de...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301908/ https://www.ncbi.nlm.nih.gov/pubmed/30574662 http://dx.doi.org/10.1186/s13550-018-0464-7 |
_version_ | 1783381882419806208 |
---|---|
author | Desvaux, Emiko Courteau, Alan Bellaye, Pierre-Simon Guillemin, Mélanie Drouet, Camille Walker, Paul Collin, Bertrand Decréau, Richard A. |
author_facet | Desvaux, Emiko Courteau, Alan Bellaye, Pierre-Simon Guillemin, Mélanie Drouet, Camille Walker, Paul Collin, Bertrand Decréau, Richard A. |
author_sort | Desvaux, Emiko |
collection | PubMed |
description | PURPOSE: Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with (18)F-fluoromisonidazole (FMISO) for drug development purposes. METHODS: Colon cancer model was induced in mice by subcutaneous injection of 1 × 10(6) CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. RESULTS: There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI mapping. Tumour-to-background ratio was significantly higher for CLI compared with PET and MRI. Immunohistochemistry confirmed tumour hypoxia. The imaging workflow with CLI was about eight times faster than the PET-MRI procedure. CONCLUSION: CLI is a fast and relevant tool to assess tumour hypoxia. This approach could be particularly interesting for hypoxia-targeting drug development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13550-018-0464-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6301908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-63019082019-01-04 Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo Desvaux, Emiko Courteau, Alan Bellaye, Pierre-Simon Guillemin, Mélanie Drouet, Camille Walker, Paul Collin, Bertrand Decréau, Richard A. EJNMMI Res Short Communication PURPOSE: Molecular imaging techniques visualise biomarkers for both drug development and personalised medicine. In this field, Cherenkov luminescence imaging (CLI) seems to be very attractive by allowing imaging with clinical PET radiotracers with high-throughput capabilities. In this context, we developed a fast CLI method to detect tumour hypoxia with (18)F-fluoromisonidazole (FMISO) for drug development purposes. METHODS: Colon cancer model was induced in mice by subcutaneous injection of 1 × 10(6) CT-26 cells. FMISO was injected, and simultaneous PET-blood oxygen level dependent (BOLD)-MRI followed by CLI were performed along with immunohistochemistry staining with pimonidazole. RESULTS: There was a significant correlation between FMISO PET and CLI tumour uptakes, consistent with the BOLD-MRI mapping. Tumour-to-background ratio was significantly higher for CLI compared with PET and MRI. Immunohistochemistry confirmed tumour hypoxia. The imaging workflow with CLI was about eight times faster than the PET-MRI procedure. CONCLUSION: CLI is a fast and relevant tool to assess tumour hypoxia. This approach could be particularly interesting for hypoxia-targeting drug development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13550-018-0464-7) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-12-20 /pmc/articles/PMC6301908/ /pubmed/30574662 http://dx.doi.org/10.1186/s13550-018-0464-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Short Communication Desvaux, Emiko Courteau, Alan Bellaye, Pierre-Simon Guillemin, Mélanie Drouet, Camille Walker, Paul Collin, Bertrand Decréau, Richard A. Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title | Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title_full | Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title_fullStr | Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title_full_unstemmed | Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title_short | Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
title_sort | cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301908/ https://www.ncbi.nlm.nih.gov/pubmed/30574662 http://dx.doi.org/10.1186/s13550-018-0464-7 |
work_keys_str_mv | AT desvauxemiko cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT courteaualan cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT bellayepierresimon cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT guilleminmelanie cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT drouetcamille cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT walkerpaul cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT collinbertrand cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo AT decreauricharda cherenkovluminescenceimagingisafastandrelevantpreclinicaltooltoassesstumourhypoxiainvivo |